Search results for "ECIS"

showing 10 items of 2868 documents

S-Detect characterization of focal breast lesions according to the US BI RADS lexicon: a pictorial essay

2020

High-resolution ultrasonography (US) is a valuable tool in breast imaging. Nevertheless, US is an operator-dependent technique: to overcome this issue, the American College of Radiology (ACR) has developed the breast imaging-reporting and data system (BI-RADS) US lexicon. Despite this effort, the variability in the assessment of focal breast lesions (FBLs) with the use of BI-RADS US lexicon is still an issue. Within this framework, evidence shows that computer-aided image analysis may be effective in improving the radiologist’s assessment of FBLs. In particular, S-Detect is a newly developed image-analytic computer program that provides assistance in morphologic analysis of FBLs seen on US …

medicine.medical_specialtyBI-RADSBreast imagingProblem-solvingBreast NeoplasmsBI-RADSLexicon030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineImage Interpretation Computer-AssistedComputer-assisted diagnosiInternal MedicinemedicineHumansRadiology Nuclear Medicine and imagingMedical physicsBreastUltrasonographyBreast neoplasmbusiness.industryGeneral MedicineRadiology Information Systems030220 oncology & carcinogenesisPictorial EssayFemaleUltrasonography MammaryUltrasonographySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessDecision-makingJournal of Ultrasound
researchProduct

A meta-review of literature reviews assessing the capacity of patients with severe mental disorders to make decisions about their healthcare

2020

Abstract Background Determining the mental capacity of psychiatric patients for making healthcare related decisions is crucial in clinical practice. This meta-review of review articles comprehensively examines the current evidence on the capacity of patients with a mental illness to make medical care decisions. Methods Systematic review of review articles following PRISMA recommendations. PubMed, Scopus, CINAHL and PsycInfo were electronically searched up to 31 January 2020. Free text searches and medical subject headings were combined to identify literature reviews and meta-analyses published in English, and summarising studies on the capacity of patients with serious mental illnesses to m…

medicine.medical_specialtyBipolar DisorderMeta-reviewlcsh:RC435-571Bipolar disorderDecision MakingPsychological interventionContext (language use)PsycINFOCINAHLlcsh:PsychiatryMentally Ill PersonsHealth caremedicineHumansMental CompetencyDecision making capacityBipolar disorderPsychiatryLiterature reviewbusiness.industryBipolar disorder Decision making capacity Literature review Mental disorder Meta-review SchizophreniaMental DisordersMental illnessmedicine.diseaseSelf CarePsychiatry and Mental healthMental disorderPsychotic DisordersSchizophreniaSchizophreniabusinessResearch Article
researchProduct

Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets

2016

Abstract The European Society of Hypertension recommend the following main rules for treatment of hypertension in elderly and octogenarians: 1) In elderly hypertensives with SBP ≥ 160 mmHg there is solid evidence to recommend reducing SBP to between 140 mmHg and 150 mmHg. 2) In fit elderly patients less than 80 years old treatment may be considered at SBP ≥ 140 mmHg with a target SBP < 140 mmHg if treatment is well tolerated. 3) In fit individuals older than 80 years with an initial SBP ≥ 160 mmHg it is recommended to reduce SBP to between 150 mmHg and 140 mmHg. 4) In frail elderly patients, it is recommended to base treatment decisions on comorbidity and carefully monitor the effects of tr…

medicine.medical_specialtyBlood Pressure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicinemedicineHumansFrail elderly030212 general & internal medicineIntensive care medicineBlood pressure-lowering treatmentAgedAged 80 and overoctogenarianbusiness.industryGeneral Medicineblood pressure targetmedicine.diseaseComorbidityelderly patientEuropeBlood pressureEuropean Society of HypertensionHypertensionIsolated systolic hypertensionTreatment decision makingCardiology and Cardiovascular MedicinebusinessBlood Pressure
researchProduct

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A pros…

2015

We performed a multicenter study to validate the concept that a simple comprehensive geriatric assessment (CGA) can identify elderly, non-fit patients with diffuse large B-cell lymphoma (DLBCL) in whom curative treatment is not better then palliation, and to analyze potential benefits of treatment modulation after further subdividing the non-fit category by CGA criteria. One hundred and seventy-three patients aged &gt; 69 treated with curative or palliative intent by clinical judgement only were grouped according to CGA into fit (46%), unfit (16%) and frail (38%) categories. Two-year overall survival (OS) was significantly better in fit than in non-fit patients (84% vs. 47%; p &lt; 0.0001).…

medicine.medical_specialtyCancer ResearchMultivariate analysisLymphomaChemotherapeutic approaches; Immunotherapy; Lymphoma and Hodgkin disease; Hematology; Oncology; Cancer ResearchMEDLINEDisease-Free SurvivalInternal medicineComprehensive Assesment Diffuse large B cell lymphomaAntineoplastic Combined Chemotherapy Protocolsmedicine80 and overLarge B-CellHumansProspective StudiesProspective cohort studyGeriatric AssessmentAgedAged 80 and overChemotherapeutic approachesbusiness.industryPalliative CareGeriatric assessmentHematologymedicine.diseasePrognosisDiffuseSurgeryLymphomaSettore MED/15 - MALATTIE DEL SANGUETreatment OutcomeMulticenter studyOncologyLymphoma and Hodgkin diseaseMultivariate AnalysisTreatment decision makingImmunotherapyLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?

2021

Prediabetes is defined as a condition of abnormal glucose metabolism, characterised by plasma glucose above normal range but not as high as required for the diagnosis of diabetes mellitus (DM). It represents a heterogeneous entity of intermediate glucose metabolism, including impaired fasting glucose, impaired glucose tolerance, and borderline glycated haemoglobin. Prediabetes is being increasingly recognised as an important metabolic state not only predisposing to a higher probability of future progression to DM, but also to an increased risk of different micro- and macrovascular complications. The recently proposed sub-phenotyping of individuals at increased risk of type 2 DM, which disti…

medicine.medical_specialtyCardiovascular disease Diabetes mellitus Kidney disease Precision medicine Prediabetes Type 2 diabetes mellitusEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyImpaired glucose tolerance03 medical and health sciencesDiabetes mellitus0302 clinical medicineDiabetes mellitusInternal medicineType 2 diabetes mellitusInternal MedicineMedicinePrediabetesDisease burdenbusiness.industryPrecision medicineType 2 Diabetes MellitusKidney diseaseCardiovascular diseasemedicine.diseaseImpaired fasting glucoseCommentarybusinessPrediabetesKidney diseaseDiabetes Therapy
researchProduct

Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature.

2016

NAFLD (Non-Alcoholic Fatty Liver Disease) is an increasingly significant public health issue, regarded as the most relevant liver disease of the twenty-first century. Approximately 20%-30% of NAFLD subjects develop a NASH (Non-Alcoholic Steato-Hepatitis), a condition which can potentially evolve to liver cirrhosis and hepatocellular carcinoma. For these reasons a proper evaluation of liver damage is a key point for diagnosis and prognosis and liver biopsy still remains the "gold standard" procedure both for discrimination between steatosis and steatohepatitis and assessment of the degree of liver fibrosis. Nonetheless, given it is an invasive, painful and costly procedure, a great research …

medicine.medical_specialtyCirrhosisFibrosiBiopsyClinical Decision-MakingApoptosis030204 cardiovascular system & hematologyBiochemistryGastroenterologyMultimodal Imaging03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineMedicineAnimalsHumansMortalityMolecular BiologyLiver injurymedicine.diagnostic_testAnimalbusiness.industryFatty liverApoptosiBiomarkerGeneral Medicinemedicine.diseasePrognosisFibrosisdigestive system diseasesAlgorithmLiverLiver biopsyHepatocellular carcinomaMolecular Medicine030211 gastroenterology & hepatologySteatosisSteatohepatitisMorbiditybusinessAlgorithmsBiomarkersHumanCurrent molecular medicine
researchProduct

Informing MS patients on treatment options: a consensus on the process of consent taking

2020

Abstract\ud In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient’s empowerment in the decision-making process.\ud Aims\ud The aims of our project were to review the strategies used by Italian MS specialists to inform patients about treatment options and to design a multicentre shared document that homogenizes the information about disease-modifying treatment (DMTs) and the procedure of taking informed consent in clinical practice.\ud Results\ud The new resource, obtained by consensus among 31 neurologists from 27 MS Centres in Italy with the…

medicine.medical_specialtyConsensusProcess (engineering)media_common.quotation_subjectDermatologyDisease modifying treatment; Informed consent; Multiple sclerosisMultiple sclerosis03 medical and health sciences0302 clinical medicineResource (project management)Informed consentDisease modifying treatmentmedicineHumans030212 general & internal medicineInformed consentEmpowermentmedia_commonPhysician-Patient Relationsbusiness.industryTreatment optionsGeneral MedicineClinical PracticePsychiatry and Mental healthItalyFamily medicineDisease modifying treatment; Informed consent; Multiple sclerosis; Consensus; Humans; Italy; Physician-Patient Relations; Informed Consent; Multiple SclerosisSettore MED/26 - NeurologiaNeurology (clinical)Decision processbusiness030217 neurology & neurosurgery
researchProduct

Cost-effectiveness analysis of robot-assisted vs. open partial nephrectomy

2017

Background The cost-effectiveness of robot-assisted partial nephrectomy (RAPN) vs. the open procedure is not established. Methods We estimated in-hospital complications and the cost of RAPN vs. open partial nephrectomy (OPN) using an economic model. Costs incurred both intraoperatively and in hospital were considered. US data were extracted from existing literature. Results Mean in-hospital costs were $14,824 (95% CI $13,368-$16,898) for RAPN and $15,094 (95% CI $13,491-$17,140) for OPN. Complications after RAPN occurred in 23.3% (95% CI 20.0-25.8%) and after OPN in 36.1% (95% CI 35.6-36.6%) of the patients. In a sensitivity analysis, limited centre experience was associated with relevant i…

medicine.medical_specialtyCost-Benefit Analysismedicine.medical_treatment030232 urology & nephrologyBiophysicsNephrectomy03 medical and health sciencesPostoperative Complications0302 clinical medicineRobotic Surgical ProceduresmedicineHumansOpen partial nephrectomyHospital CostsComputer-assisted surgerybusiness.industryDecision TreesPerioperativeCost-effectiveness analysisNephrectomyComputer Science ApplicationsSurgeryModels EconomicTreatment Outcome030220 oncology & carcinogenesisSurgeryLower costbusinessThe International Journal of Medical Robotics and Computer Assisted Surgery
researchProduct

Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges

2021

Abstract The application of imaging biomarkers in oncology is still in its infancy, but with the expansion of radiomics and radiogenomics a revolution is expected in this field. This may be of special interest in head and neck cancer, since it can promote precision medicine and personalization of treatment by overcoming several intrinsic obstacles in this pathology. Our goal is to provide the medical oncologist with the basis to approach these disciplines and appreciate their main uses in clinical research and clinical practice in the medium term. Aligned with this objective we analyzed the most relevant studies in the field, also highlighting novel opportunities and current challenges.

medicine.medical_specialtyDecision MakingRadiogenomicsPersonalizationMedium termMachine LearningRadiomicsBiomarkers TumormedicineHumansRadiology Nuclear Medicine and imagingMedical physicsPrecision MedicineSquamous Cell Carcinoma of Head and Neckbusiness.industryHead and neck cancerGeneral MedicinePrognosismedicine.diseasePrecision medicineHead and neck squamous-cell carcinomaPatient managementOncologyHead and Neck NeoplasmsbusinessDiagnostic Techniques RadioisotopeCancer Treatment Reviews
researchProduct

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct